The AD brain exhibits insulin resistance, and T2DM is a major risk factor for AD [1–3, 31]; therefore, insulin secretagogues which can induce MUTYH degradation are promising therapeutic agents for the prevention of the AD pathogenesis. Here, INS is linked to Insulin resistance.